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. Monoclonal antibodies used for immunophenotyping of leukemia patients by flow cytometry. Table S2 . Total number, average age and gender distribution of leukemia patients included in the study. Table S3 . Sensitivity of tumor cells to chemotherapeutic drugs (WST-test data), treatment regimens and therapy response of patients with acute and chronic leukemia with scales for correlation analysis (in parentheses). Table S4 . Immunological markers and cytogenetic abnormalities detected in tumor cells of patients with acute and chronic leukemia with scales for correlation analysis (in parentheses). Table S5 . Correlation coefficients reflecting the relationships between the drug sensitivity and expression of immunological markers in tumor cells of patients with acute myeloid leukemia. Table S6 . Correlation coefficients reflecting the relationships between the drug sensitivity and cytogenetic abnormalities in tumor cells of leukemia patients. Table S7 . Correlation coefficients reflecting the relationships between the drug sensitivity and expression of immunological markers in tumor cells of patients with acute lymphoblastic leukemia. Table S8 . Correlation coefficients reflecting the relationships between the drug sensitivity and expression of immunological markers in tumor cells of patients with chronic lymphocytic leukemia. Table S9 . Correlation coefficients reflecting the relationships between the drug sensitivity, MDR1 mRNA and P-glycoprotein expression in tumor cells of leukemia patients. 7+3: cytarabine 100-200 mg/m2 intravenously (1-7 days) + daunorubicin 45 mg/m2 intravenously (1-3 days) 7+3+VP: cytarabine 100-200 mg/m2 intravenously (1-7 days) + daunorubicin 45 mg/m2 intravenously (1-3 days) + etoposide 120 mg/m2 intravenously (17-21 days) 5+2: cytarabine 100-200 mg/m2 intravenously once a day (1-5 days) + daunorubicin 45 mg/m2 intravenously (1, 2 days) 6-MP: 6-mercaptopurine 50 mg/m2 intravenously Low-dose cytarabine-7, -14, -21, -28 : 10 mg/m2 subcutaneously twice a day (during 7, 14, 21 or 28 days) Intermediate-dose cytarabine-7: 600 mg/m2 twice a day (during 7 days) HAM: high-dose cytarabine 3g/m2 intravenously twice a day (1-3 days) + mitoxantrone 10 mg/m2 intravenously (3-5 days) HiDAC: high-dose cytarabine 3g/m2 intravenously twice a day (1, 3, 5 days) High-dose cyclophosphamide: 7 g/m2 intravenously + G-CSF 5 mg/kg intravenously VAD: vincristine 0.4 mg/m2 intravenously (1-4 days) + adriablastine 10 mg/m2 intravenously (1-4 days) + dexamethasone 40 mg/m2 per os (1-4 days, 11-14 days) dexamethasone 30 mg/m2 intravenously (148-150 days) + cytarabine 2 g/m2 intravenously + L-asparaginase 10000 U/m2 intravenously -maintenance: vincristine 2 mg intravenously (1-3 days) + daunorubicin 45 mg/m2 intravenously (1-3 days) + dexamethasone 10 mg/m2 per os (1-3 days) + 6-mercaptopurine 50 mg/m2 per os (4-28 days) + methotrexate 30 mg/m2 intravenously (2, 9, 16, 23 days) + L-asparaginase 10000 U/m2 intravenously (3, 10 days) + methotrexate 15 mg, cytarabine 30 mg, dexamethasone 4 mg intrathecally (once in three month) RACOP: daunorubicin 45 mg/m2 intravenously (1-3 days) + cytarabine 100 mg/m2 intravenously twice a day (1-7 days) + cyclophosphamide 400 mg/m2 intravenously (1-7 days) + vincristine 2 mg intravenously (1, 7 days) + prednisolone 60 mg/m2 per os (1-7 days) COMP: cyclophosphamide 1 g/m2 intravenously (1 day) + vincristine 2 mg intravenously (1 day) + methotrexate 12.5 mg/m2 intravenously (3, 4 days) + prednisolone 100 mg/m2 per os (1-5 days) COAP: cyclophosphamide 400 mg/m2 intravenously (1 day) + vincristine 2 mg intravenously (1 day) + cytarabine 60 mg/m2 intravenously twice a day (1-5 days) + prednisolone 40 mg/m2 per os (1-5 days) COP: cyclophosphamide 0.8-1 g/m2 intravenously (1 day) + vincristine 1.4 mg/m2 intravenously (1 day) + prednisolone 60 mg/m2 per os (1-5 days) R-COP: rituximab 375 mg/m2 intravenously (day 1 during cycle 1) and rituximab 500 mg/m2 intravenously (day 1 during other cycles) + cyclophosphamide 0.8-1 g/m2 intravenously (1 day) + vincristine 1.4 mg/m2 intravenously (1 day) + prednisolone 60 mg/m2 per os (1-5 days) CHOP: cyclophosphamide 750 mg/m2 intravenously (1 day) + doxorubicin 50 mg/m2 intravenously (1 day) + vincristine 1.4 mg/m2 intravenously (1 day) + prednisolone 40 mg/m2 per os (1-5 days) R-CHOP: rituximab 375 mg/m2 intravenously (day 1 during cycle 1) and rituximab 500 mg/m2 intravenously (day 1 during other cycles) + cyclophosphamide 750 mg/m2 intravenously (1 day) + doxorubicin 50 mg/m2 intravenously (1 day) + vincristine 1.4 mg/m2 intravenously (1 day) + prednisolone 40 mg/m2 per os (1-5 days) miniCHOP: cyclophosphamide 600 mg/m2 intravenously (1 day) + doxorubicin 25 mg/m2 intravenously (1 day) + vincristine 1 mg/m2 intravenously (1 day) + prednisolone 40 mg/m2 per os (1-5 days) R-miniCHOP: rituximab 375 mg/m2 intravenously (day 1 during cycle 1) and rituximab 500 mg/m2 intravenously (day 1 during other cycles) + cyclophosphamide 600 mg/m2 intravenously (1 day) + doxorubicin 25 mg/m2 intravenously (1 day) + vincristine 1 mg/m2 intravenously (1 day) + prednisolone 40 mg/m2 per os (1-5 days) CHOEP: cyclophosphamide 750 mg/m2 intravenously (1 day) + doxorubicin 50 mg/m2 intravenously (1 day) + vincristine 1.4 mg/m2 intravenously (1 day) + prednisolone 40 mg/m2 per os (1-5 days) + etoposide 100 mg/m2 intravenously (1-3 days) R-CHOEP: rituximab 375 mg/m2 intravenously (day 1 during cycle 1) and rituximab 500 mg/m2 intravenously (day 1 during other cycles) + cyclophosphamide 750 mg/m2 intravenously (1 day) + doxorubicin 50 mg/m2 intravenously (1 day) + vincristine 1.4 mg/m2 intravenously (1 day) + prednisolone 40 mg/m2 per os (1-5 days) + etoposide 100 mg/m2 intravenously (1-3 days) DHAP: dexamethasone 10 mg/m2 intravenously 4 times a day (1-4 days) + cytarabine 2 g/m2 intravenously twice a day (2 day) + cisplatin 100 mg/m2 intravenously (1 day) R-DHAP: rituximab 375 mg/m2 intravenously (day 1 during cycle 1) and rituximab 500 mg/m2 intravenously (day 1 during other cycles) + dexamethasone 10 mg/m2 intravenously 4 times a day (1-4 days) + cytarabine 2 g/m2 intravenously twice a day (2 day) + cisplatin 100 mg/m2 intravenously (1 day) LBM-04: -prephase: cyclophosphamide 200 mg/m2 intravenously (1-5 day) + dexamethasone 20 mg per os (1-5 day) -block A: dexamethasone 20 mg per os (1-5 day) + vincristine 2 mg intravenously (1 day) + iphosphamide 800 mg/m2 intravenously (1-5 days) + methotrexate 1.5 g/m2 intravenously (1 day) + cytarabine 150 mg/m2 intravenously (4, 5 days) + vepeside 100 mg/m2 intravenously (4, 5 days) + doxorubicin 25 mg/m2 intravenously (1, 2 days) + methotrexate 15 mg, cytarabine 30 mg, dexamethasone 4 mg intrathecally (1 day) -block C: dexamethasone 20 mg per os (1-5 day) + vepeside 150 mg/m2 intravenously (3-5 days) + methotrexate 1.5 g/m2 intravenously (1 day) + vinblastine 10 mg intravenously (1 day) + cytarabine 2 g/m2 intravenously (2, 3 days) + methotrexate 15 mg, cytarabine 30 mg, dexamethasone 4 mg intrathecally (1 day) FC: fludarabine 25 mg/m2 intravenously (1-3 days) + cyclophosphamide 250 mg/m2 intravenously (1-3 days) R-FC: rituximab 375 mg/m2 intravenously (day 1 during cycle 1) and rituximab 500 mg/m2 intravenously (day 1 during other cycles) + fludarabine 25 mg/m2 intravenously (1-3 days) + cyclophosphamide 250 mg/m2 intravenously (1-3 days) R-FC-Lite: rituximab 375 mg/m2 intravenously (day 1 during cycle 1) and rituximab 500 mg/m2 intravenously (day 1 during other cycles) + fludarabine 20 mg/m2 intravenously (1-3 days) + cyclophosphamide 150 mg/m2 intravenously (1-3 days) BR: bendamustine 90 mg/m2 intravenously (1, 2 days) + rituximab 375 mg/m2 intravenously (day 1 during cycle 1) and rituximab 500 mg/m2 intravenously (day 1 during other cycles) CVP: cyclophosphamide 400 mg/m2 intravenously (1-5 days) + vincristine 1.4 mg/m2 intravenously (1 day) + prednisolone 100 mg/m2 per os (1-5 days) R-CVP: rituximab 375 mg/m2 intravenously (day 1 during cycle 1) and rituximab 500 mg/m2 intravenously (day 1 during other cycles) + cyclophosphamide 400 mg/m2 intravenously (1-5 days) + vincristine 1.4 mg/m2 intravenously (1 day) + prednisolone 100 mg/m2 per os (1-5 days) ESHAP: etoposide 60 mg/m2 intravenously (1-4 days) + cisplatin 25 mg/m2 intravenously (1-4 days) + cytarabine 2 g/m2 intravenously (1-4 days) + methylprednisolone 500 mg/m2 intravenously (1-4 days) R-ESHAP: rituximab 375 mg/m2 intravenously (day 1 during cycle 1) and rituximab 500 mg/m2 intravenously (day 1 during other cycles) + etoposide 60 mg/m2 intravenously (1-4 days) + cisplatin 25 mg/m2 intravenously (1-4 days) + cytarabine 2 g/m2 intravenously (1-4 days) + methylprednisolone 500 mg/m2 intravenously (1-4 days) 
